Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Celcuity LLC’s stock reached an all-time high of 55.58 USD, marking a significant milestone for the biotechnology company. With a current market capitalization of $2.33 billion, analysts maintain a bullish outlook, setting price targets between $60-79. According to InvestingPro analysis, the stock is currently showing signs of being overbought. This achievement comes amid a remarkable 1-year change, with the stock surging by 264.54%. The substantial increase in stock value reflects growing investor confidence and interest in Celcuity’s innovative approaches and potential within the biotech sector. InvestingPro data reveals the company maintains strong liquidity with a current ratio of 4.58, though it’s currently not profitable. As the company continues to advance its research and development efforts, this upward trend highlights the market’s positive reception of its strategic initiatives and future prospects. Discover 15+ additional exclusive insights and detailed analysis in the comprehensive Pro Research Report, available on InvestingPro.
In other recent news, Celcuity Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gedatolisib in HR+/HER2- advanced breast cancer for review under the Real-Time Oncology Review program. This development is part of Celcuity’s strategy to expedite the FDA evaluation process, with plans to complete the NDA submission by the fourth quarter of 2025. H.C. Wainwright raised its price target for Celcuity to $66, maintaining a Buy rating, following the company’s second-quarter 2025 financial results and NDA submission plans. Stifel also increased its price target to $68, highlighting the potential of gedatolisib and upcoming data presentations. Meanwhile, Needham adjusted its price target to $70 due to dilution concerns but kept a Buy rating. Jefferies raised its target to $79, citing positive progression-free survival data from a Phase III study. These developments reflect a growing interest and varied perspectives among analysts regarding Celcuity’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.